Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America
Copyright: © Martin et al..
Lung cancer is a leading cause of cancer-related deaths in Latin America, with non-small cell lung cancer (NSCLC) being the most prevalent. The current study aimed to report real-world data on epidermal growth factor receptor (EGFR) mutational testing and treatment regimens at diagnosis and progression in patients with metastatic NSCLC across four Latin American countries (Argentina, Chile, Colombia and Uruguay). A retrospective, multicenter, observational study was conducted in patients with NSCLC using medical records from participating countries. The study population was categorized into two cohorts: Cohort 1 comprised of newly diagnosed, treatment-naïve patients with stage IV NSCLC; and cohort 2 comprised of stage IV NSCLC EGFR mutation (EGFRm)-positive patients who had progressed after first- or second-generation EGFR-tyrosine kinase inhibitor (TKI) treatment. Measures included demographic variables, health characteristics, treatment regimen, molecular testing rate and turnaround time at diagnosis and at progression for cohorts 1 and 2, respectively. Descriptive statistics were used to summarize all study measures. Of the 462 patients enrolled, 431 were newly diagnosed or treatment naïve with metastatic NSCLC. In cohort 1, the majority of patients with private health insurance (57.31%) underwent molecular diagnosis while only 41.3% of patients within the public sector had access to testing. The average molecular testing rate in cohort 1 varied across countries, with Argentina having the highest testing rate (79%) and Uruguay the lowest (27.63%). EGFRm was observed in 22% of patients. Cohort 2 comprised 31 patients who had progressed after first- or second-generation EGFR-TKI treatment and of these, only 22 (70.97%) underwent testing after progression. Access to molecular testing is still a challenge impacting the choice of first-line treatment in Latin American patients with NSCLC. These findings underline the unmet needs of ensuring early diagnosis, molecular profiling and use of correct treatment to alleviate NSCLC burden in the region.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Molecular and clinical oncology - 16(2022), 1 vom: 10. Jan., Seite 6 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martin, Claudio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epidermal growth factor receptor |
|---|
| Anmerkungen: |
Date Revised 11.12.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3892/mco.2021.2439 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334175992 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334175992 | ||
| 003 | DE-627 | ||
| 005 | 20231225223144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/mco.2021.2439 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334175992 | ||
| 035 | |a (NLM)34881026 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martin, Claudio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © Martin et al. | ||
| 520 | |a Lung cancer is a leading cause of cancer-related deaths in Latin America, with non-small cell lung cancer (NSCLC) being the most prevalent. The current study aimed to report real-world data on epidermal growth factor receptor (EGFR) mutational testing and treatment regimens at diagnosis and progression in patients with metastatic NSCLC across four Latin American countries (Argentina, Chile, Colombia and Uruguay). A retrospective, multicenter, observational study was conducted in patients with NSCLC using medical records from participating countries. The study population was categorized into two cohorts: Cohort 1 comprised of newly diagnosed, treatment-naïve patients with stage IV NSCLC; and cohort 2 comprised of stage IV NSCLC EGFR mutation (EGFRm)-positive patients who had progressed after first- or second-generation EGFR-tyrosine kinase inhibitor (TKI) treatment. Measures included demographic variables, health characteristics, treatment regimen, molecular testing rate and turnaround time at diagnosis and at progression for cohorts 1 and 2, respectively. Descriptive statistics were used to summarize all study measures. Of the 462 patients enrolled, 431 were newly diagnosed or treatment naïve with metastatic NSCLC. In cohort 1, the majority of patients with private health insurance (57.31%) underwent molecular diagnosis while only 41.3% of patients within the public sector had access to testing. The average molecular testing rate in cohort 1 varied across countries, with Argentina having the highest testing rate (79%) and Uruguay the lowest (27.63%). EGFRm was observed in 22% of patients. Cohort 2 comprised 31 patients who had progressed after first- or second-generation EGFR-TKI treatment and of these, only 22 (70.97%) underwent testing after progression. Access to molecular testing is still a challenge impacting the choice of first-line treatment in Latin American patients with NSCLC. These findings underline the unmet needs of ensuring early diagnosis, molecular profiling and use of correct treatment to alleviate NSCLC burden in the region | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Latin America | |
| 650 | 4 | |a epidermal growth factor receptor | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a non-small cell lung cancer | |
| 650 | 4 | |a tyrosine kinase inhibitor | |
| 700 | 1 | |a Cuello, Mauricio |e verfasserin |4 aut | |
| 700 | 1 | |a Barajas, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Recondo, Gonzalo |e verfasserin |4 aut | |
| 700 | 1 | |a Aruachan, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Perroud, Herman |e verfasserin |4 aut | |
| 700 | 1 | |a Sena, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Bonilla, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Orlandi, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Berutti, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia Cocco, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez, Alvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Korbenfeld, Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a Zapata, Maycos |e verfasserin |4 aut | |
| 700 | 1 | |a Cundom, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Orellana, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Goncalves, Susana |e verfasserin |4 aut | |
| 700 | 1 | |a Reinhold, Florencia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular and clinical oncology |d 2013 |g 16(2022), 1 vom: 10. Jan., Seite 6 |w (DE-627)NLM236574981 |x 2049-9469 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:1 |g day:10 |g month:01 |g pages:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/mco.2021.2439 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 1 |b 10 |c 01 |h 6 | ||